Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Compassionate Use of Remdesivir in Covid-19

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Bastian Neesgaard
  • Annegret Pelchen-Matthews
  • Lene Ryom
  • Eric Florence
  • Lars Peters
  • Ashley Roen
  • Veronika Svedhem
  • Amanda Clarke
  • Thomas Benfield
  • Viktar Mitsura
  • Santiago Moreno
  • Marek Beniowski
  • Josip Begovac
  • Raimonda Matulionyte
  • Tatyana Trofimova
  • Daniel Elbirt
  • Mariana Kundro
  • Vincenzo Vullo
  • Georg Behrens
  • Therese Staub
  • Leigh Ragone
  • Vani Vannappagari
  • Jens Lundgren
  • Amanda Mocroft
  • EuroSIDA study
Vis graf over relationer

OBJECTIVE: To assess the use of two-drug antiretroviral regimens (2DR) and virologic and immunologic outcomes compared with three-drug regimens (3DR) in the EuroSIDA cohort.

DESIGN: Multicentre, prospective cohort study.

METHODS: Logistic regression was used to analyse the uptake and outcomes among HIV-positive individuals who started or switched to a 2DR compared with those on a 3DR. Virologic outcomes were assessed on-treatment as the proportion of individuals with controlled viral load (<400 copies/ml), or with a composite modified FDA snapshot endpoint (mFDA), with mFDA success defined as controlled viral load at 6 months or 12 months for individuals with a known viral load, no regimen changes, AIDS or death. Immunologic response was defined as a 100 cells/μl or a 25% increase in CD4 cell counts from baseline.

RESULTS: Between 1 July 2010 and 31 December 2016, 423 individuals started or switched to a 2DR (eight antiretroviral-naive) and 4347 started a 3DR (566 naive). Individuals on 2DR tended to have suppressed viral load, higher CD4 cell counts and more comorbidities at baseline compared with those on 3DR. There were no differences in the proportions of individuals who obtained on-treatment or mFDA success, and no significant differences in the adjusted odds ratios for mFDA success or immunologic responses between the 2DR and 3DR groups at 6 months or 12 months.

CONCLUSION: In routine clinical practice, 2DR were largely used for virologically suppressed individuals with higher cumulative exposure to antiretrovirals and comorbidities. Virologic and immunologic outcomes were similar among those on 2DR or 3DR, although confounding by indication cannot be fully excluded due to the observational nature of the study.

OriginalsprogEngelsk
TidsskriftAIDS
Vol/bind33
Udgave nummer13
Sider (fra-til)2013-2024
Antal sider12
ISSN0269-9370
DOI
StatusUdgivet - 1 nov. 2019

ID: 57712284